×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
Yahoo Finance
June 4, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of...
1 hour ago
Argenx isn't sweating over Vyvgart competitors: exec
Fierce Pharma
Since its commercial debut in late 2021, argenx has touted the potential for Vyvgart as a pipeline in a product. But while Vyvgart is faring...
3 weeks ago
Biohaven Tumbles After Protein-Degrading Drug Misses Expectations
Investor's Business Daily
Biohaven stock tumbled Wednesday after the company's experimental protein-degrading drug lagged investor expectations.
5 days ago
Principal Financial Group Inc. Has $1.13 Million Stock Position in argenx SE (NASDAQ:ARGX)
Defense World
Read Principal Financial Group Inc. Has $1.13 Million Stock Position in argenx SE (NASDAQ:ARGX) at Defense World.
21 hours ago
Argenx stock plunges 23% on failed study for autoimmune disease drug
MSN
Argenx (NASDAQ:ARGX) stock plunged 23% after the company reported that topline results from a Phase 3 study for its drug candidate efgartigimod subcutaneous...
2 days ago
Argenx readies a blockbuster opportunity with drug for autoimmune disease
STAT
The company has developed the IgG-lowering antibody Vyvgart to treat patients with chronic inflammatory demyelinating polyneuropathy,...
2 months ago
Argenx Earnings: Maintaining Our Fair Value Estimates as Vyvgart Is Approaching CIDP Approval
Morningstar
We're maintaining our $466/EUR 425 fair value estimates for Argenx following first-quarter results that were in line with our expectations,...
3 weeks ago
Argenx to stop clinical development of efgartigimod for AAV
ANCA Vasculitis News
Argenx is not advancing its development plans for efgartigimod in AAV, after considering Phase 3 trial data in two other autoimmune...
3 weeks ago
Argenx gears up to launch Vyvgart in next potential indication
Fierce Pharma
Argenx on Tuesday gave a detailed glimpse at positive data from its late-stage ADHERE trial testing Vyvgart Hytrulo—the subcutaneous version of...
1 month ago
argenx announces results of Annual General Meeting of Shareholders
Yahoo Finance
May 7, 2024 – 5:30pm ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving...
4 weeks ago